Branded generic medicines marketed to Indian doctors through field forces and sold through chemists - the core of the Indian pharmaceutical market (IPM).
Sun Pharmaceutical IndustriesOperator · HighListed
Mankind PharmaOperator · HighListed
Torrent PharmaceuticalsOperator · HighListed
Alkem LaboratoriesOperator · HighListed
Abbott IndiaOperator · HighListed
Eris LifesciencesOperator · HighListed
CiplaOperator · MediumListed
Zydus LifesciencesOperator · MediumListed
Ipca LaboratoriesOperator · MediumListed
Ajanta PharmaOperator · MediumListed
Intas PharmaceuticalsOperator · HighUnlisted
Ipca Laboratories (IPCALAB)
Vertically integrated maker of branded formulations (pain - Zerodol, anti-malarials, cardiac) and APIs, with Unichem adding US/Europe generics
Price
₹1,928
snapshot 30 Oct 2026
Strengths
Backward integration into its own APIs protects margins in pain and anti-malarial franchises
India branded growth consistently above market in pain/rheumatology
Unichem acquisition (2023) gives a ready US and European generics platform
Risks
Past USFDA import alert (2015) on key sites still shapes US ambitions
Anti-malarial institutional business is tender-driven and lumpy
Unichem integration and margin repair are still in progress
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Turns molecules into brands: companies in-license or make formulations, build them into doctor-recognised brands through large medical-representative (MR) field forces, and sell through ~65,000 stockists to India's chemists. In India almost every off-patent medicine is a 'branded generic', so brand and prescriber loyalty, not patents, decide market share.
Why it matters
This is the steadiest and highest-return profit pool in Indian pharma: no US-style price erosion, high gross margins (60-80%), modest capex and cash-rich balance sheets. It is also where the sector's best compounders (Sun's India business, Torrent, Abbott India, Mankind) live, and why consolidation deals in this layer command 30x+ EBITDA.
Where the value pool sits
Pharmarack puts the IPM at ~₹2.4L Cr for calendar 2025 (+8.1%), with August 2026 value growth of 10.7%. Growth is mostly price and new launches (annual WPI-linked hikes on NLEM drugs, freer pricing on non-scheduled brands); volume growth is near zero. Chronic therapies (cardiac, anti-diabetic, CNS, GI) grow faster and are stickier than acute ones (anti-infectives, respiratory), so chronic-heavy portfolios earn premium valuations.
Key drivers
Chronic disease burden (diabetes, hypertension, obesity) and rising insurance coverage
Patent expiries in India (sitagliptin 2022, empagliflozin 2025, semaglutide Mar 2026) creating large new branded-generic markets
Brand acquisitions from MNCs and smaller peers (Torrent-JB, Mankind-Bharat Serums, Eris-Biocon brands)
Annual WPI-linked price increases on scheduled drugs plus up to 10% a year on non-scheduled brands
Potential bottlenecks
Price control: ~15-18% of the market sits under NLEM/DPCO ceiling prices, and NPPA can cap trade margins or add drugs to the list
Field-force productivity - MR costs rise every year and incremental reps add less
Trade-generic and Jan Aushadhi channels pressure prices in commoditised molecules
Revised Schedule M (WHO-GMP aligned) raises compliance cost for smaller makers
Investor metrics to watch
IPM share and rank (Pharmarack / IQVIA)
Domestic growth vs IPM growth, split into price / volume / new launches